Deqsiga (Human Normal Immunoglobulin)

Deqsiga contains mainly immunoglobulin G (IgG), with a broad spectrum of antibodies against infectious agents. This therapeutic drug is used to treat people who:

• are at risk of infection because they lack a type of antibody called immunoglobulin G (IgG), which is a protein in the blood that helps the body fight infections. DEQSIGA is used in people who are born with a lack of IgG (primary immunodeficiency syndrome, PID) and those who develop a lack of IgG after birth (secondary immunodeficiency syndrome, SID) and have infections that are severe or keep coming back, and for which medicines used to treat infections do not work.
• have certain immune diseases (caused by the body’s own defence system attacking normal tissues), to help the activity of the immune system (immunomodulation). Deqsiga is used in patients with:
• primary immune thrombocytopenia (ITP), a disease associated with a lack of platelets (components in the blood that help it to clot), which puts patients at risk of bleeding;
• Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), inflammatory disorders of the nerves that result in muscle weakness and numbness.
• Kawasaki disease, a disease mainly seen in children which causes inflammation of blood vessels.
• multifocal motor neuropathy (MMN), nerve damage that causes weakness of the arms and legs.

Recommended Dosage:
The recommended dosage of Deqsiga is determined by a doctor experienced in treating patients with immune system disorders. Dosage is administered by infusion (drip) into a vein. Patients with immunodeficiency receive this medicine every 3 to 4 weeks. How often this therapeutic drug is administered for immunomodulation depends on the condition being treated.

• Serious allergic reactions may occur with Deqsiga 100 mg/ml, especially in patients with IgA deficiency. Symptoms may include rash, itching, swelling, wheezing, or difficulty breathing. Discontinue immediately if hypersensitivity occurs. Emergency treatment should be available during infusion.
• Acute renal dysfunction or failure has been reported, particularly with sucrose-containing products, high doses, or pre-existing renal impairment. Monitor kidney function closely, ensure adequate hydration, and use the lowest effective dose. Patients with diabetes or dehydration are at higher risk.
• Thromboembolic events such as stroke, deep vein thrombosis, myocardial infarction, or pulmonary embolism can occur. Risk factors include advanced age, prolonged immobilization, or clotting disorders. Administer at the lowest feasible dose and infusion rate. Maintain hydration and monitor for symptoms promptly.
• Aseptic meningitis may occur within hours to days of infusion. Symptoms include severe headache, neck stiffness, fever, nausea, and sensitivity to light. Discontinue treatment if suspected. Diagnosis should be confirmed, and symptoms usually resolve after stopping immunoglobulin therapy.
• Deqsiga may cause intravascular or extravascular hemolysis due to antibodies present in the product. Monitor patients for anemia, jaundice, dark urine, or fatigue. Hemolysis can be severe in rare cases. Laboratory testing may be required if hemolysis is suspected.
• Transfusion-Related Acute Lung Injury (TRALI) is a rare but serious reaction involving acute respiratory distress, low oxygen levels, and non-cardiogenic pulmonary edema. It may develop within hours of infusion. Stop infusion immediately if suspected and provide supportive respiratory care, including oxygen supplementation or mechanical ventilation.
• Since this therapeutic drug is derived from human plasma, there is a theoretical risk of transmitting infectious agents, including viruses or prions. Rigorous donor screening and viral inactivation reduce this risk but do not eliminate it completely. Patients should be informed before use.
• The safety of Deqsiga during pregnancy has not been fully established. Use only if clearly needed and if potential benefits outweigh risks. Human immunoglobulins cross the placenta and may influence neonatal immunity. Careful monitoring of the mother and baby is recommended.
• This medicine is excreted into breast milk and may affect the nursing infant’s immunity. The clinical significance remains unclear, but caution should be exercised. Healthcare providers should weigh the benefits for the mother against the potential risks for the infant before recommending breastfeeding continuation.

What documents are required to import DEQSIGA to India?

DEQSIGA (Human Normal Immunoglobulin) injection can be imported by patients or government hospitals in the name of the patients only.

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is DEQSIGA available in India?

DEQSIGA (Human Normal Immunoglobulin injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of DEQSIGA in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

DEQSIGA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of DEQSIGA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork-in-253190.hostingersite.com for Deqsiga 100 mg/ml injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source DEQSIGA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Deqsiga®?

Human Normal Immunoglobulin is the Generic Name for the trade name drug Deqsiga®.

What is the Manufacturer’s Name of Deqsiga®?

Deqsiga® is manufactured by Takeda Manufacturing Austria AG.

Is Deqsiga approved by the FDA?

No, Deqsiga® is not approved by the U.S. FDA; its authorization is limited to specific international regulatory regions, including the EU.

What is the dosage and form of Deqsiga® supplied?

Deqsiga® is supplied in the form of Injections: 100 mg/ml solution for infusion, administered by infusion (drip) into a vein.

What are the most common side effects of Deqsiga® 100 mg/ml injection?

The most commonly reported side effects of Deqsiga® are flatulence (gas), abdominal (belly) pain, constipation, headache, nausea, diarrhoea, cholelithiasis, and reactions at the injection site.

How much does Deqsiga® 100 mg/ml injection cost in India?

Deqsiga® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Deqsiga prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Deqsiga 100 mg/ml cost in India, please call/WhatsApp +91-9310090915 or send an email to info@indianpharmanetwork-in-253190.hostingersite.com.

Can Deqsiga® 100 mg/ml injections be available in SAARC countries?

Apart from Gulf countries, Deqsiga® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Deqsiga® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Deqsiga® 100 mg/ml injection online in India?

Yes, one can buy Deqsiga 100 mg/ml online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the legal supply of Deqsiga® injection through legal channels.

What are the storage conditions of Deqsiga® 100 mg/ml injections?

Store Deqsiga® 100 mg/ml injections below 25°C, protected from light, and kept in original packaging. Do not freeze. Keep out of children’s reach.